Another Neuromodulator on the Horizon

The SAKURA 1 and 2 Phase 3 trials included 609 patients total. “The demographics in these trials all look the same – probably the same as in our practices,” said Kenneth Beer, M.D.

Four weeks post-treatment, approximately 74% of patients treated with daxibotulinumtoxinA achieved at least 2-point improvements in investigator- and subject-assessed glabellar line scores (versus zero and 1% for placebo, respectively; p<0.0001). Also at week 4, 88% and 91% of daxibotulinum toxin-treated patients were either satisfied or very satisfied with their results.

Dr. Beer is associate clinical professor of dermatology at the University of Miami Miller School of Medicine, consulting associate with Duke University, clinical associate in dermatology, University of Pennsylvania Perelman School of Medicine and a CBC cofounder.

For additional details or to register for future CBC events, please contact: